BioNotebook: Denovo, Celimmune revive Lilly, Amgen programs; Malin invests in Serenus; J&J opens fourth incubator; Blueprint, Alexion partner
This article was originally published in Scrip
Executive Summary
What's old is new again as San Diego-based Denovo Biopharma has licensed a second failed Eli Lilly drug and Celimmune in Lebanon, New Jersey has licensed a monoclonal antibody that's been sitting on Amgen's shelf since 2008.
You may also be interested in...
Finance Watch: Investors Bet Billions On Big Biopharma Offerings
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.